DrugPatentWatch Database Preview
Details for Biologics License Application: 125326
» See Plans and Pricing
Summary for BLA: 125326
| Tradename: | ARZERRA |
| Applicant: | Novartis |
| Ingredient: | ofatumumab |
| Patents: | 130 |
| Approval Date: | Oct 26, 2009 |
| Suppliers: see list | 1 |
Pharmacology for BLA: 125326
| Drug Class | CD20-directed Cytolytic Antibody |
| Mechanism of Action | CD20-directed Antibody Interactions |
US Patents for BLA: 125326
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis | ARZERRA | ofatumumab | INJECTABLE; INJECTION | 125326 | 001 | 2009-10-26 | Start Trial | SIO2 MEDICAL PRODUCTS, INC. (Auburn, AL) | 2033-03-11 | RX | search | |
| Novartis | ARZERRA | ofatumumab | INJECTABLE; INJECTION | 125326 | 001 | 2009-10-26 | Start Trial | The United States of America, as represented by the Secretary, Department of Health and Human Services (Washington, DC) University of Virginia Patent Foundation (Charlottesville, VA) | 2034-01-08 | RX | search | |
| Novartis | ARZERRA | ofatumumab | INJECTABLE; INJECTION | 125326 | 001 | 2009-10-26 | Start Trial | AbbVie Stemcentrx LLC (North Chicago, IL) | 2033-02-08 | RX | search | |
| Novartis | ARZERRA | ofatumumab | INJECTABLE; INJECTION | 125326 | 001 | 2009-10-26 | Start Trial | University of the Sciences of Philadelphia (Philadelphia, PA) | 2034-11-21 | RX | search | |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
